

PU4760USw

Remarks

Currently Claims 1-3 and 6-32 are pending. Claims 4-5 and 27 are canceled herein. Claims 1, 22, 26 and 28 are amended herein.

The Examiner has required restriction between claims of:

Examiner's Group (I): claims 1-3, 5-22(part) and 23-28 wherein Y¹ is N; and


Examiner's Group (II): claims 1-4, 6-22(part) and 23-28 wherein Y¹ is CH.

Applicants hereby elect the Examiner's Group (II), wherein Y¹ is CH, for prosecution on the merits in this case. Applicants expressly reserve the right to file one or more divisional applications directed toward the subject matter of Examiner's Group (I). For purposes of expediting allowance of the now-pending claims, the claims have been amended to remove non-elected subject matter. Entry of the instant amendment is respectfully requested.

The Examiner is respectfully requested to consider the references submitted in the IDS and PTO-1449's filed on 20 August 2004 and 7 March 2006, and to provide an Initialed copy of the PTO-1449s with the next communication.

Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 12 Jan 2007
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
lorie.a.morgan@gsk.com